Clinical trials: Psoriasis, completed
Psoriasis
Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis
Safety and Efficacy study of AVT04 (Alvotech Biosimilar to Ustekinumab), in patients with moderate to severe plaque psoriasis
- Trial name
- NCT04930042
- Testing
- Stelara, AVT04
- Where
- 30 sites in Estonia, Georgia and 2 more
- Volunteers
- 581 people
- Sponsor
- Alvotech Swiss AG
Psoriasis Vulgaris
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris
This study will compare efficacy and safety of once daily treatment of calcipotriol plus betamethasone dipropionate gel (LEO 80185) with tacalcitol ointment and LEO 80185 vehicle alone in subjects with psoriasis vulgaris.
- Trial name
- NCT00670241
- Testing
- calcipotriol and betamethasone (LEO 80185 gel), LEO 80185 vehicle, Tacalcitol ointment
- Where
- Canada
- Volunteers
- 458 people
- Sponsor
- LEO Pharma
Psoriasis
HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.
The goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737.
- Trial name
- NCT07712705
- Testing
- HPP737
- Where
- 50 sites in China
- Volunteers
- 515 people
- Sponsor
- Newsoara Biopharma Co., Ltd.
Psoriatic Arthritis
Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis
Study BCD-085-8/PATERA is a multicentre double-blind placebo-controlled Phase 3 study in patients with psoriatic arthritis (PsA).
- Trial name
- PATERA (NCT03598751)
- Testing
- BCD-085
- Where
- 3 sites in Belarus, Russia
- Volunteers
- 194 people
- Sponsor
- Biocad
Psoriasis
Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis
Merrimack is conducting a research study to see if an experimental drug, called MM-093, is safe and effective in the treatment of psoriasis.
- Trial name
- NCT00147329
- Testing
- MM-093
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Merrimack Pharmaceuticals
Psoriasis
Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)
Subjects with psoriasis will receive intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 (induction therapy) to evaluate the efficacy of infliximab at Week 18.
- Trial name
- TIPS (NCT00686686)
- Testing
- Infliximab
- Volunteers
- 23 people
- Sponsor
- Merck Sharp & Dohme LLC
Nail Psoriasis
Evaluation of the Efficacy and Safety of Indigo Naturalis Oil Extract on Psoriatic Nails
The purpose of this study is to evaluate efficacy and safety of indigo naturalis oil extract in treating nail psoriasis.
- Trial name
- NCT00999687
- Testing
- Indigo Naturalis Extract in Oil, Olive Oil
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Psoriatic Arthritis
A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi®
This is a randomized, double-blind, parallel three-arm, and single-dose Phase I clinical study, designed to compare the similarity of pharmacokinetics, safety and immunogenicity between BAT2506 Injection and Simponi® (EU-licensed…
- Trial name
- NCT05332730
- Testing
- BAT2506 injection, Simponi® (EU commercially available product), Simponi® (US commercially available product)
- Where
- China
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Bio-Thera Solutions
Psoriasis
Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques.
- Trial name
- NCT04908475
- Testing
- Risankizumab, Apremilast
- Where
- 54 sites in United States, Canada and 3 more
- Volunteers
- 352 people
- Sponsor
- AbbVie
Psoriasis Vulgaris, Psoriatic Arthritis
A Phase 4 Clinical Study of Brodalumab
This study [4827-005 (post market)] is designed to evaluate the safety and efficacy of long-term exposure to brodalumab in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic arthritis) who have completed Study 4827-003…
- Conditions
- Psoriasis Vulgaris, Psoriatic Arthritis, Pustular; Psoriasis, Palmaris Et Plantaris, Psoriatic Erythroderma
- Trial name
- NCT04183881
- Testing
- Brodalumab 210mg SC
- Where
- Japan
- Volunteers
- 138 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Moderate to Severe Palmar Plantar Psoriasis
Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis
The purpose of this study is to determine the short and long term safety and effectiveness of ustekinumab in subjects with moderate to severe chronic palmar plantar psoriasis.
- Trial name
- PPP (NCT01090063)
- Testing
- Ustekinumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Tufts Medical Center
Plaque Psoriasis
Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients
This study is to evaluate the efficacy and safety of M518101 and the dose relationship among two doses of M518101 and placebo in male and female plaque psoriasis patients.
- Trial name
- NCT01301157
- Testing
- M518101, Dovonex
- Where
- 32 sites in United States
- Volunteers
- 294 people
- Sponsor
- Maruho Co., Ltd.
Psoriasis
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
The primary objectives of the study are to 1) compare the efficacy responses of CP 690,550 (5 mg BID and 10 mg BID) versus placebo following 24 weeks of CP 690,550 treatment and subsequent withdrawal of active treatment at…
- Trial name
- NCT01186744
- Testing
- CP-690,550
- Where
- 87 sites in United States, Argentina and 10 more
- Volunteers
- 666 people
- Sponsor
- Pfizer
Psoriasis, Plaque Psoriasis
An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis when administered every 2 weeks.
- Trial name
- CIMPASI-1 (NCT02326298)
- Testing
- Certolizumab Pegol
- Where
- 30 sites in United States, Canada and 3 more
- Volunteers
- 234 people
- Sponsor
- UCB Biopharma S.P.R.L.
Psoriatic Arthritis, Psoriasis
The Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Psoriatic arthritis (PsA) is a type of joint disease that can lead to severe joint damage and disability within the first few years of the disease.
- Conditions
- Psoriatic Arthritis, Psoriasis, Non-Inflammatory Rheumatic Conditions
- Trial name
- DUET (NCT04587362)
- Testing
- Musculoskeletal Ultrasound
- Where
- Canada
- Volunteers
- 419 people
- Sponsor
- Women's College Hospital
Psoriasis
HPP737 in Adult Patients With Plaque Psoriasis
The goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737.
- Trial name
- NCT07712731
- Testing
- HPP737, Apremilast
- Where
- 60 sites in China
- Volunteers
- 607 people
- Sponsor
- Newsoara Biopharma Co., Ltd.
Psoriatic Arthritis
Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial
SPEED is a three arm interventional trial nested within a cohort (Trials Within Cohorts or TWiCs design). This tests more aggressive early therapy in patients newly diagnosed with moderate to severe PsA.
- Trial name
- SPEED (NCT03739853)
- Testing
- Methotrexate, Sulfasalazine, Leflunomide
- Where
- United Kingdom
- Volunteers
- 192 people
- Sponsor
- University of Oxford
Inflammatory Skin Disease, Psoriasiform Dermatoses, Eczematiform Dermatoses, Lichenoid Dermatoses, Psoriasis, Eczema, Lichen, Lupus, Dermatomyositis
Interest of LC-OCT for Diagnosing Inflammatory Dermatoses: ODIN (OCT Dermotoses INflammatoires)
Inflammatory dermatoses (eczematiform dermatoses, psoriasiform dermatoses, lichenoid dermatoses, toxic dermatoses, auto-immune and auto-inflammatory dermatoses, etc.) and their differential diagnoses (infectious or…
- Trial name
- ODIN (NCT06874712)
- Where
- France
- Volunteers
- 210 people
- Sponsor
- Hospices Civils de Lyon
Psoriasis
Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis
The primary objective is to assess differences in PASI scores between Week 12 of Study C87040 [NCT00245765] and Week 12 of re-treatment in this study.
- Trial name
- NCT00329303
- Testing
- Certolizumab Pegol (Cimzia®)
- Where
- 14 sites in France, Germany
- Volunteers
- 71 people
- Sponsor
- UCB Pharma
Psoriasis Vulgaris
Vasoconstriction Trial With LEO 90100 Aerosol Foam
Vasoconstriction study with LEO 90100
- Trial name
- NCT02973776
- Testing
- LEO 90100 aerosol foam, Dermoval®/Dermovate®, Diprosone
- Where
- France
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- LEO Pharma